Browsing Tag
MOLBREEVI
2 posts
Savara Inc. (NASDAQ: SVRA) moves closer to first approval as FDA files MOLBREEVI BLA with priority review
Savara Inc. has secured FDA priority review for MOLBREEVI in autoimmune PAP. Find out what this means for approval odds, investors, and rare lung care.
Savara’s $130m stock offering strengthens cash position ahead of MOLBREEVI launch
Savara raises $130 million through stock and warrant sale to fund MOLBREEVI’s rare-disease launch—find out how this deal reshapes its commercialization path.